EMO Biomedicine Corp.   Report issue

For profit Phase 1
Founded: Taipei Taiwan (2004)

Organization Overview

First Clinical Trial
2017
NCT03007576
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

EMO Biomedicine Corporation

Active Ingredients

Drugs in Phase 1 Trials (1)

autologous mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 1)

Osteoarthritis, Knee (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1